Our medication development program for cocaine abuse is based on using the acute and chronic withdrawal periods as windows of treatment opportunity. We have previously demonstrated that these periods are characterized by mechanistic flux, during which, not only cocaine ensitization/consolidation take place, but also previously established sensitization and/or progressive ratio cocaine self administration can be reversed with 5-HT3 or 5-HT2A antagonists. The animal data with these antagonists are consistent with clinical data demonstrating that dozapine, a mixed 5-HT3 and 5-HT2 antagonist, substantially reduces stimulant abuse in both schizophrenics and drug abusers. The present proposal emphasizes the use of a non-abused drug (e.g., mazindol or pergolide) to simulate daily acute cocaine withdrawal, which is subsequently targeted with a 5-HT3, 5-HT2A or NMDA antagonists. Mazindol increases both dopamine and 5-HT neurotransmission by uptake inhibition, while pergolide has high agonist affinity at both D2 and 5-HT2A receptors. Our proposed treatment strategy is not only to reverse previously established cocaine sensitization but also to maintain the de-sensitized state and thus facilitate cocaine abstinence. We will rapidly screen putative treatment regimens with locomotor measurement and behavior rating; treatments exhibiting significant efficacy reversing behavioral sensitization will be subsequently examined for reversal of progressive ratio self-administration and neurobiological sensitization markers. Our neurobiological markers include the ones that have been repeatedly demonstrated to be associated with sensitization establishment following chronic cocaine injections and subsequent withdrawal (e.g., NR2B / GluR1 subunit expression, dopamine/glutamate efflux). To the extent that sensitization is involved in recidivism in cocaine abusers, our medication development program provides a road map for treatment intervention that is based not only on specific drugs, but perhaps more importantly, on the treatment dosing regimen. We hypothesize that, when used on a daily basis by human abusers, a combination of non-abused stimulant and an antagonist administered during the ensuing acute withdrawal period may promote long-term maintenance of a desensitized state or abstinence. ? ?

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Project (R01)
Project #
5R01DA012768-07
Application #
6903400
Study Section
Human Development Research Subcommittee (NIDA)
Program Officer
Acri, Jane
Project Start
1999-09-30
Project End
2009-03-31
Budget Start
2005-04-01
Budget End
2006-03-31
Support Year
7
Fiscal Year
2005
Total Cost
$346,500
Indirect Cost
Name
Duke University
Department
Psychiatry
Type
Schools of Medicine
DUNS #
044387793
City
Durham
State
NC
Country
United States
Zip Code
27705
Lee, Tong H; Szabo, Steven T; Fowler, J Corey et al. (2012) Pharmacologically-mediated reactivation and reconsolidation blockade of the psychostimulant-abuse circuit: a novel treatment strategy. Drug Alcohol Depend 124:11-8
Bhatia, Kamal S; Szabo, Steven T; Fowler, J Corey et al. (2011) Reversal of long-term methamphetamine sensitization by combination of pergolide with ondansetron or ketanserin, but not mirtazapine. Behav Brain Res 223:227-32
Chen, Qiang; Zhu, Xiongzhao; Zhang, Yu et al. (2010) Integrin-linked kinase is involved in cocaine sensitization by regulating PSD-95 and synapsin I expression and GluR1 Ser845 phosphorylation. J Mol Neurosci 40:284-94
Nah, Seong-Yeol; Bhatia, Kamal S; Lyles, Johnnie et al. (2009) Effects of ginseng saponin on acute cocaine-induced alterations in evoked dopamine release and uptake in rat brain nucleus accumbens. Brain Res 1248:184-90
Yuan, Langtian; Seo, Jin-Soo; Kang, Nam Sook et al. (2009) Identification of 3-hydroxy-2-(3-hydroxyphenyl)-4H-1-benzopyran-4-ones as isoform-selective PKC-zeta inhibitors and potential therapeutics for psychostimulant abuse. Mol Biosyst 5:927-30
Davidson, Colin; Lazarus, Cindy; Xiong, Xueying et al. (2002) 5-HT2 receptor antagonists given in the acute withdrawal from daily cocaine injections can reverse established sensitization. Eur J Pharmacol 453:255-63
Davidson, Colin; Lazarus, Cindy; Lee, Tong H et al. (2002) Behavioral sensitization is greater after repeated versus single chronic cocaine dosing regimens. Eur J Pharmacol 441:75-8
Davidson, Colin; Lee, Tong H; Xiong, Zhiping et al. (2002) Ondansetron given in the acute withdrawal from a repeated cocaine sensitization dosing regimen reverses the expression of sensitization and inhibits self-administration. Neuropsychopharmacology 27:542-53
Davidson, C; Gow, A J; Lee, T H et al. (2001) Methamphetamine neurotoxicity: necrotic and apoptotic mechanisms and relevance to human abuse and treatment. Brain Res Brain Res Rev 36:1-22